A specific mutation has been linked with acquired resistance in immunotherapy drugs used to treat non–small lung cancer (NSCLC).
A specific mutation has been linked with acquired resistance in immunotherapy drugs used to treat non—small lung cancer (NSCLC).
Researchers led by cancer biologist Katerina Politi, PhD, associate professor in the Yale Department of Pathology and Medical Oncology, have discovered that a mutation in a viral protein called B2M prevents the immune activation needed for immunotherapy agents to function. The discovery of this new resistance mechanism explains why some patients develop resistance later on in treatment and may also steer the evolution of future NSCLC drug development.1
For patients with NSCLC who are not candidates for other targeted therapies, immunotherapy is considered to be a viable treatment alternative. Immunotherapy drugs that have earned FDA approval to treat NSCLC include breakthrough therapies like nivolumab and pembrolizumab, as well as the most recent agent, atezolizumab.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More